For research use only. Not for therapeutic Use.
Lefamulin（Cat No.:I007398）is a pleuromutilin antibiotic used to treat community-acquired bacterial pneumonia (CABP) in adults. It acts by binding to the 50S ribosomal subunit, inhibiting bacterial protein synthesis and effectively targeting respiratory pathogens, including Streptococcus pneumoniae, Haemophilus influenzae, and atypical bacteria like Mycoplasma pneumoniae. Lefamulin is available in both oral and intravenous formulations, offering flexibility in treatment settings. Its novel mechanism of action and efficacy against multidrug-resistant strains make it a valuable option in the management of respiratory infections, especially where traditional antibiotics may be ineffective.
| Catalog Number | I007398 |
| CAS Number | 1061337-51-6 |
| Synonyms | BC-3781; BC 3781; BC3781; Lefamulin;(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-hydroxy-4,7,9,12-tetramethyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]annulen-5-yl 2-(((1R,2R,4R)-4-amino-2-hydroxycyclohexyl)thio)acetate |
| Molecular Formula | C28H45NO5S |
| Purity | ≥95% |
| Solubility | Soluble in DMSO |
| Storage | 0 - 4°C for short term , or -20°C for long term. |
| IUPAC Name | [(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-3-hydroxy-2,4,7,14-tetramethyl-9-oxo-6-tricyclo[5.4.3.01,8]tetradecanyl] 2-[(1R,2R,4R)-4-amino-2-hydroxycyclohexyl]sulfanylacetate |
| InChI | InChI=1S/C28H45NO5S/c1-6-26(4)14-22(34-23(32)15-35-21-8-7-18(29)13-20(21)31)27(5)16(2)9-11-28(17(3)25(26)33)12-10-19(30)24(27)28/h6,16-18,20-22,24-25,31,33H,1,7-15,29H2,2-5H3/t16-,17+,18-,20-,21-,22-,24+,25+,26-,27+,28+/m1/s1 |
| InChIKey | KPVIXBKIJXZQJX-FCEONZPQSA-N |
| SMILES | C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@@]1([C@@H](C[C@@]([C@H]([C@@H]3C)O)(C)C=C)OC(=O)CS[C@@H]4CC[C@H](C[C@H]4O)N)C |
| Reference | <br /> |
